the cooperation between hmena overexpression and her2 signalling in breast cancer合作hmena超表达,在乳腺癌her2的信号.pdf

The Cooperation between hMena Overexpression and HER2 Signalling in Breast Cancer 2 3 4,5 1 1,6 Francesca Di Modugno , Marcella Mottolese , Lucia DeMonte , Paola Trono , Michele Balsamo , 1,7 3 8 9 10 Andrea Conidi , Elisa Melucci , Irene Terrenato , Francesca Belleudi , Maria Rosaria Torrisi , Massimo 5 10 ` 1 Alessio , Angela Santoni , Paola Nistico * 1 Laboratory of Immunology, Regina Elena National Cancer Institute, Rome, Italy, 2 Experimental Chemotherapy, Regina Elena National Cancer Institute, Rome, Italy, 3 Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy, 4 Tumor Immunology, Dibit, San Raffaele Scientific Institute, Milan, Italy, 5 Proteome Biochemistry, Dibit, San Raffaele Scientific Institute, Milan, Italy, 6 Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America, 7 Department of Molecular and Developmental Genetics, VIB11, Katholieke Universiteit Leuven, Leuven, Belgium, 8 Department of Epidemiology, Regina Elena National Cancer Institute, Rome, Italy, 9 Azienda Ospedaliera S. Andrea, Rome, Italy, 10 Department of Clinical and Molecular Medicine, University ‘Sapienza’, Rome, Italy Abstract hMena and the epithelial specific isoform hMena11a are actin cytoskeleton regulatory proteins belonging to the Ena/VASP family. EGF treatment of breast cancer cell lines upregulates hMena/hMena11a expressio